The FDA says abacavir (Ziagen) does not cause cardiovascular problems, opening the door for GSK to combine it with their new integrase inhibitor for naive patients

Leave a Comment / Blogger, Uncategorized / By admin1

This will make it possible for GSK-ViiV to market their new Trii formulation of the new integrase inhibitor GSK572 (generic name: dolutegravir) plus Epzicom (abacavir plus epivir) as a once a day pill for naive patients

It contradicts all the previous studies that said that abacavir (Ziagen) causes increased cardiovascular risks.

https://www.aidsmap.com/page/1682771/

GSK is currently enrolling studies to get dolutegravir approved. This drug may have activity against HIV with raltegravir resistance. More on this soon.